TMCnet News
BIND Therapeutics to Report Third Quarter 2014 Financial Results on November 6, 2014CAMBRIDGE, Mass. --(Business Wire)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced it will report third quarter 2014 financial results on Thursday, November 6, 2014. BIND's management team will host a conference call and audio webcast on Thursday, November 6, 2014 at 8:30 a.m. Eastern Time to discuss the quarterly results and recent business developments. To access the conference call, please dial (877) 312-5844 (domestic) or (253) 237-1152 (international) at least five minutes prior to the start time and refer to conference ID 24248993. A live audio webcast of the call will also be available on the Investors & Media section of the company's website, www.bindtherapeutics.com. An archived webcast will be available on the Company's website approximately two hours after the event. About BIND Therapeutics BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for the treatment of non-small cell lung cancer and metastatic castrate-resistant prostate cancer. BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB and F. Hoffmann-La Roche Ltd. to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. BIND's platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women's Hospital/Harvard Medical School of BIND's scientific founders Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the Company's web site at www.bindtherapeutics.com.
|
